STAAR Surgical Company (NASDAQ: STAA) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
STAAR Surgical Company's current Maz Rating and its five factor grades are for members: log in to see them.
At $25.56, STAAR Surgical Company trades at 2542.4x trailing earnings, 3.9x sales and 3.4x book value, with an EV/EBITDA of 69.5. Over the last twelve months it generated about $330M of revenue and $504697 of net income. It runs a gross margin of 73.1%, an operating margin of 6.7% and a net margin of 0.2%. It shows return on equity of 0.1%, return on invested capital of 0.5% and a free cash flow yield of 1.4%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 4.68. Over the past 52 weeks the share price ranged from $15.59 to $35.87, with a beta of 1.20.
STAAR Surgical Company does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 5 Buy, 9 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of October 2026, STAAR Surgical Company (STAA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 17.7% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 17.7% / 33% · Receivables / Mkt Cap (36m) 7.43% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 17.7% / 33.33% · Receivables / Mkt Cap (24m) 7.43% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 39.7% / 33.33% · Receivables / Avg Assets (4Q) 17.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 42.5% / 33.33% · (Cash+Recv) / Total Assets 60.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of October 2026, STAAR Surgical Company (STAA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. STAAR Surgical Company is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
STAAR Surgical Company reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated October 2, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.